Company / Working Capital
10x Genomics, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$531.0M
FY2025
5-year range
$466.8M / $637.2M
FY2021-FY2025
Trend
+13.8%
vs FY2024
Sector context
#62 of 165
Health Care
What the data says
At $531M, 10x Genomics, Inc.'s working capital ranks #62 of 165 in the Health Care sector. Working Capital returned to growth in FY2025 after 4 years of decline, reaching $531M.
Based on SEC 10-K filings.
$531M in FY2025 with a 5-year CAGR of -4.1%.
Improved from $469M to $531M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +1.7%
- 5-Year CAGR
- -4.1%
- 10-Year CAGR
- -
Sector benchmark
#62 of 165 in Health CareTop 38% of 165This company $531.0M Sector average $814.4M
▼
-34.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -4.1%, indicating a declining trend.
- In FY2025, working capital increased 13.8% year-over-year.
- Ranks #62 out of 165 companies in the Health Care sector.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $531.0M | +13.8% |
| FY2024 | $466.8M | -0.4% |
| FY2023 | $468.9M | -7.0% |
| FY2022 | $504.1M | -20.9% |
| FY2021 | $637.2M | -2.9% |
| FY2020 | $656.2M | +57.1% |
| FY2019 | $417.8M | +465.5% |
| FY2018 | $73.9M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026